Jean-François Spinella

ORCID

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 4

Top Venues

Blood advances

This page only lists publications with an associated author ORCID identifier.

Publications

Julien M P Grenier, Céline Testut, Matthieu Bal, Florence Bardin, Maria De Grandis, Véronique Gelsi-Boyer, Julien Vernerey, Marjorie Delahaye, Samuel Granjeaud, Christophe Zemmour, Jean-François Spinella, Triantafyllos Chavakis, Stéphane J C Mancini, Jean-Marie Boher, Josée Hébert, Guy Sauvageau, Norbert Vey, Juerg Schwaller, Marie-Anne Hospital, Cyril Fauriat, Michel A Aurrand-Lions
Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML. Blood advances 8 (17) (2024)
Julien M P Grenier, Céline Testut, Matthieu Bal, Florence Bardin, Maria De Grandis, Véronique Gelsi-Boyer, Julien Vernerey, Marjorie Delahaye, Samuel Granjeaud, Christophe Zemmour, Jean-François Spinella, Triantafyllos Chavakis, Stéphane J C Mancini, Jean-Marie Boher, Josée Hébert, Guy Sauvageau, Norbert Vey, Juerg Schwaller, Marie-Anne Hospital, Cyril Fauriat, Michel A Aurrand-Lions
Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML. Blood advances 8 (17) (2024)
Julien M P Grenier, Céline Testut, Matthieu Bal, Florence Bardin, Maria De Grandis, Véronique Gelsi-Boyer, Julien Vernerny, Marjorie C Delahaye, Samuel Granjeaud, Christophe Zemmour, Jean-François Spinella, Triantafyllos Chavakis, Stephane Jc Mancini, Jean-Marie Boher, Josée Hébert, Guy Sauvageau, Norbert Vey, Juerg Schwaller, Marie-Anne Hospital, Cyril Fauriat, Michel A Aurrand-Lions
Genetic deletion of JAM-C in pre-leukemic cells rewires leukemic stem cell gene expression program in AML. Blood advances (2024)
Céline Moison, Jean-François Spinella, Jalila Chagraoui, Vincent-Philippe Lavallée, Bernhard Lehnertz, Clarisse Thiollier, Isabel Boivin, Nadine Mayotte, Tara MacRae, Anne Marinier, Josée Hébert, Guy Sauvageau
HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition. Blood advances 6 (16) (2022)

Jean-François Spinella.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jean-François Spinella